Search
CSL's revenue rose 7.9 per cent to $US8.53 billion.

CSL drug sales lift FY profit to $US1.92bn

CSL's full-year profit has risen 11 per cent to $US1.92 billion ($A2.82 billion), driven by disease diagnosis and global demand for its immunoglobulin portfolio.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

CSL

BNiQ Disclaimer